{"public_id":"cl_4e224afb12399621dc051e6b46b2a6ca","status":"active","superseded_by_public_id":null,"corpus_id":25407135,"text":"Adding bevacizumab to FOLFOX4 improves the overall response rate compared with FOLFOX4 alone in previously treated metastatic colorectal cancer.","confidence":0.98,"paper":{"corpus_id":25407135,"title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200.","url":"https://sah.borca.ai/papers/25407135"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.98,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_54e75a4a6f128b9f4fa2baef115ed7c9","name":"overall response rate","description":"The proportion of patients whose tumors show a predefined response to treatment.","types":["outcome measure","endpoint"],"url":"https://sah.borca.ai/concepts/co_54e75a4a6f128b9f4fa2baef115ed7c9"},{"public_id":"co_5b081104717ef704f1bf2f36c96bc403","name":"FOLFOX4","description":"An oxaliplatin-based chemotherapy regimen combining oxaliplatin, fluorouracil, and leucovorin.","types":["chemotherapy regimen","treatment"],"url":"https://sah.borca.ai/concepts/co_5b081104717ef704f1bf2f36c96bc403"},{"public_id":"co_bff3d4453c16bca060cadefac9a1070d","name":"bevacizumab","description":"A monoclonal antibody that inhibits vascular endothelial growth factor and is used as an antiangiogenic cancer therapy.","types":["drug","therapeutic agent"],"url":"https://sah.borca.ai/concepts/co_bff3d4453c16bca060cadefac9a1070d"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_4e224afb12399621dc051e6b46b2a6ca"}